Role of fragile histidine triad protein expression in pathogenesis of malignant pleural mesothelioma

References

• Emri S, Akbulut H, Zorlu F, et al. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer 2001; 33: 109–14
   PubMed Web of Science ®Google Scholar
• McDonald A D, McDonald J. Malignant mesothelioma in North America. Cancer 1980; 46: 1650–6
   PubMed Web of Science ®Google Scholar
• Senyigit A, Babayigit C, Gokirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the Southeast of Turkey. Respiration 2000; 67: 610–4
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Zanesi N, Palamarchuk A, et al. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3: 748–54
   PubMed Web of Science ®Google Scholar
• Ohta M, Inoue H, Cottecelli M G, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587–97
   PubMed Web of Science ®Google Scholar
• Mascaux C, Martin B, Verdebout J M, et al. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53. Eur Respir J 2003; 21: 753–8
   PubMed Web of Science ®Google Scholar
• Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004; 100: 1605–14
   PubMed Web of Science ®Google Scholar
• Huang L W, Chao S L, Chen T J. Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. Gynecol Oncol 2003; 90: 331–7
   PubMed Web of Science ®Google Scholar
• Fouts R L, Sandusky G E, Zhang S, et al. Down-regulation of fragile histidine triad-expression in prostate carcinoma. Cancer 2003; 97: 1447–52
   PubMed Web of Science ®Google Scholar
• Baffa R, Gomella L G, Vecchione A, et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 2000; 156: 419–24
   PubMed Web of Science ®Google Scholar
• Pylkkänen L, Wolff H, Stjernvall T, et al. Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch 2004; 444: 43–48
   PubMed Web of Science ®Google Scholar
• Cakir C, Gulluoglu M G, Yilmazbayhan D. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology 2006; 38: 10–15
   PubMed Web of Science ®Google Scholar
• Sington J D, Morris L S, Nicholson A G, et al. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma. Histopathology 2003; 42: 498–502
   PubMed Web of Science ®Google Scholar
• Kahlos K, Soini Y, Paakko P, et al. Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int J Cancer 2000; 88: 37–43
   PubMed Web of Science ®Google Scholar
• Lumb P D, Suvarna S K. Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease. Histopathology 2004; 44: 345–52
   PubMed Web of Science ®Google Scholar
• Otero-Garcia J E, Youssef E, Enamorado I I, et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. Am J Otolaryngol 2004; 25: 231–9
   PubMed Web of Science ®Google Scholar
• Stein C K, Glover T W, Plamer J L, et al. Direct correlation between FRA3B expression and cigarette smoking. Genes Chomosomes Cancer 2002; 34: 333–40
   PubMed Web of Science ®Google Scholar
• Siprashvili Z, Sozzi G, Barnes L D, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771–6
   PubMed Web of Science ®Google Scholar
• Mineta H, Miura K, Takebayashi S, et al. Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma. Oral Oncol 2002; 39: 56–63
   Web of Science ®Google Scholar
• Zimmerman R L. FHIT protein is expressed in benign mesothelium and has no clinical value in detecting carcinoma in body cavity effusions. Appl Immunohistochel Mol Morphol 2000; 8: 154–7
   PubMed Web of Science ®Google Scholar
• Nelson H H, Wiencke J K, Gunn L, et al. Chromosome 3p14 alterations in lung cancer: Evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998; 58: 1804–7
   PubMed Web of Science ®Google Scholar
• Comin C E, Anichini C, Boddi V, et al. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 2000; 36: 26–31
   PubMed Web of Science ®Google Scholar
• Hirano H, Tsuji M, Kizaki T, et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med Electron Microsc 2002; 35: 16–23
   PubMedGoogle Scholar
• Toledo G, Sola J J, Lozano M D, et al. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol 2004; 17: 440–8
   PubMed Web of Science ®Google Scholar
• Arun B, Kilic G, Yen C, et al. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 2005; 14: 1681–5
   PubMed Web of Science ®Google Scholar
• Fischer J R, Ohnmacth U, Rieger N, et al. Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006; 54: 109–16
   PubMed Web of Science ®Google Scholar
• Croce C M, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618–24
   PubMed Web of Science ®Google Scholar